Abstract: The present invention provides compositions comprising an isolated or purified therapeutically effective hPCSK9 polypeptide derived from the hPCSK9 catalytic domain, and their use in methods of treating hypercholesterolemia.
Abstract: The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (?) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said short-chain peptides, and pharmaceutical compositions containing them and their use.
Abstract: A BM23 peptide is obtained by mutating and modifying BMP-2. The BM23 peptide improves stability and duration of in-vivo efficacy relative to BMP-2, has an activity of promoting the differentiation of bone marrow mesenchymal stem cells into chondrocytes and promoting the proliferation of chondrocytes and can be used for repairing cartilage and/or treating osteoarthritis.
Abstract: This invention relates to methods of producing collagen biomaterials by admixing (i) a solution of monomeric collagen, (ii) a solution of polymeric collagen, (ii) cargo particles, and (iv) a non-collagen blocking polymer, to produce a collagen solution. The collagen solution is then allowed to solidify to produce a collagen hydrogel. This may be useful in improving the stiffness of collagen hydrogel constructs and increasing the entrapment and retention of cargo particles.
Abstract: Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.
Type:
Grant
Filed:
May 23, 2018
Date of Patent:
January 7, 2020
Assignee:
3M Innovative Properties Company
Inventors:
Jerald K. Rasmussen, Kannan Seshadri, Robert T. Fitzsimons, Jr., James I. Hembre, Catherine A. Bothof, Erin A. Satterwhite, George W. Griesgraber, Yi He, Louis C. Haddad
Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
Abstract: Provided herein are novel fluorogenic and bioluminescent bacterial protease substrates that contain at least one bacterial protease cleavage site. In some embodiments, the proteases that cleave the protease substrates are bacterial proteases including those used for tissue dissociation, cell isolation, and cell detachment, such as the preparation of islet cells. Additionally, the novel protease substrates described herein may be used to assess the activity of certain bacterial proteases involved in isolating primary cells and stem cells. Methods and protease detection kits using the novel protease substrates are also provided herein.
Abstract: The iCP-RF recombinant protein of present invention could mediate generation of the induced pluripotent stem cells (iPSCs) from terminally differentiated somatic cells.
Abstract: The present invention provides: a peptide which shows a hair growth-promoting activity and/or a melanin generation-promoting activity; a composition for preventing and/or alleviating hair loss, comprising the peptide as an effective ingredient; a composition for promoting hair growth, comprising the peptide as an effective ingredient; a use of the peptide for preventing and/or alleviating hair loss; a use of the peptide for promoting hair growth; a pharmaceutical composition for preventing and/or treating hypomelanosis, comprising the peptide as an effective ingredient; a cosmetic composition for preventing and/or treating hypomelanosis, comprising the peptide as an effective ingredient; and a use of the peptide for preventing and/or treating hypomelanosis.
Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
Abstract: The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.
Abstract: A thio-selective radioactive labeling agent has the following general formula: *R-L-VS, wherein said *R is a radioisotope, L is a linking group, and VS is a vinylsulfone functional group.
Type:
Grant
Filed:
March 8, 2014
Date of Patent:
November 12, 2019
Assignees:
University of Southern California, City of Hope
Inventors:
Zibo Li, Peter S. Conti, Lin Li, Zhanhong Wu, Shuanlong Liu, John E. Shively, David Horne
Abstract: The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.
Type:
Grant
Filed:
July 1, 2016
Date of Patent:
November 5, 2019
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Loren D. Walensky, Rida Mourtada, Gregory H. Bird
Abstract: The present invention relates to an RGD motif-containing peptide or a fragment thereof, which is used to effectively treat burns and glaucoma, obtain an excellent effect of alleviating skin wrinkles, and is effective in the promotion of hair restoration and hair growth as well as the prevention of hair loss. Therefore, the motif-containing peptide or the fragment thereof can be utilized for a cosmetic composition and a pharmaceutical composition.
Type:
Grant
Filed:
December 31, 2015
Date of Patent:
November 5, 2019
Assignee:
HUONS CO., LTD.
Inventors:
Key-An Um, Yeong-Mok Kim, Jong Hwan Lim
Abstract: A soluble human single-chain T cell receptor (TCR) having the structure: V?2-L-V? or V?-L-V?2, wherein L is a linker peptide that links V? with V?, V? is a TCR variable ? region, and V?2 is a TCR variable ? region of the family 2 is provided. The provided scTCR is useful for many purposes, including the treatment of cancer, viral diseases and autoimmune diseases.
Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.
Abstract: The present invention relates to a polypeptide comprising at least one signaling domain and a potassium sensor which is capable of binding K+ and the first signaling domain is capable of generating a detectable signal upon binding of K+ to the potassium sensor. The invention also relates to a polynucleotide encoding said polypeptide and the use of the polypeptide in various applications for the detection of K+.
Type:
Grant
Filed:
May 9, 2018
Date of Patent:
October 1, 2019
Assignee:
MEDIZINISCHE UNIVERSITÄT GRAZ
Inventors:
Emrah Eroglu, Helmut Bischof, Wolfgang Graier, Roland Malli, Markus Waldeck-Weiermair
Abstract: Isoform-selective lysine deacetylase inhibitors are described. Inhibitors of the lysine deacetylase enzyme are useful as antitumor drugs and for treating addiction, asthma, cardio-vascular disease, immunosuppression, neurodegenerative diseases, sepsis, sickle-cell disease, uveal melanoma and termination of viral latency, particularly HIV-1 latency.
Type:
Grant
Filed:
May 5, 2016
Date of Patent:
September 24, 2019
Assignee:
Washington University
Inventors:
Garland R. Marshall, George B. Kyei, Michael D. Onken, Lee Ratner, Nandarapu Damodara Reddy
Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
September 10, 2019
Assignees:
Technische Universität München, Biotechnologicky Ustav AV CR, v.v.i.
Inventors:
Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.
Type:
Grant
Filed:
January 7, 2013
Date of Patent:
August 20, 2019
Assignee:
Omniox, Inc.
Inventors:
Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary